These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29878662)

  • 1. Bioengineered molecules for the management of haemophilia: Promise and remaining challenges.
    Pipe SW
    Haemophilia; 2018 May; 24 Suppl 6():68-75. PubMed ID: 29878662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The past and future of haemophilia: diagnosis, treatments, and its complications.
    Peyvandi F; Garagiola I; Young G
    Lancet; 2016 Jul; 388(10040):187-97. PubMed ID: 26897598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gene therapy of haemophilia - has the cure come within reach?].
    Kaczmarek R
    Postepy Biochem; 2018 Dec; 64(4):318-322. PubMed ID: 30656916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 7. Haemophilia.
    Cahill MR; Colvin BT
    Postgrad Med J; 1997 Apr; 73(858):201-6. PubMed ID: 9156121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemophilia: factoring in new therapies.
    Fassel H; McGuinn C
    Br J Haematol; 2021 Sep; 194(5):835-850. PubMed ID: 34322873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of factor VIII and factor IX mutations, HLA Class II, tumour necrosis factor-α and interleukin-10 on inhibitor development among Thai haemophilia A and B patients.
    Chuansumrit A; Sasanakul W; Sirachainan N; Kadegasem P; Wongwerawattanakoon P; Mahaklan L; Nathalang O
    Haemophilia; 2017 Nov; 23(6):e518-e523. PubMed ID: 28891589
    [No Abstract]   [Full Text] [Related]  

  • 10. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR
    Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemophilia therapies.
    Dargaud Y; Negrier C
    Expert Opin Biol Ther; 2007 May; 7(5):651-63. PubMed ID: 17477803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical gene therapy for haemophilia.
    Chuah MK; Collen D; Vandendriessche T
    Haemophilia; 2004 Oct; 10 Suppl 4():119-25. PubMed ID: 15479384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of the prevalence of clotting factor deficiency in carriers of haemophilia A and haemophilia B.
    Boban A; Lambert C; Lannoy N; Hermans C
    Haemophilia; 2017 Sep; 23(5):e471-e473. PubMed ID: 28689376
    [No Abstract]   [Full Text] [Related]  

  • 15. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemophilia gene therapy: From trailblazer to gamechanger.
    Evens H; Chuah MK; VandenDriessche T
    Haemophilia; 2018 May; 24 Suppl 6():50-59. PubMed ID: 29878653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended half-life clotting factor concentrates: results from published clinical trials.
    Young G; Mahlangu JN
    Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous gene therapy for haemophilia.
    Fakharzadeh SS
    Expert Opin Biol Ther; 2004 Jun; 4(6):763-6. PubMed ID: 15174959
    [No Abstract]   [Full Text] [Related]  

  • 19. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
    Miller CH; Benson J; Ellingsen D; Driggers J; Payne A; Kelly FM; Soucie JM; Craig Hooper W;
    Haemophilia; 2012 May; 18(3):375-82. PubMed ID: 22103590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.